SXTP Profile
60 Degrees Pharmaceuticals, Inc. is a specialized pharmaceutical firm dedicated to the development and commercialization of advanced therapies aimed at preventing and treating a range of infectious diseases. The company’s flagship product, Arakoda, is utilized for malaria prevention, representing a key component in its portfolio of disease-fighting solutions.
In addition to Arakoda, 60 Degrees Pharmaceuticals is advancing several innovative treatments through its research and development pipeline. The company is progressing with Tafenoquine, currently in Phase IIb clinical trials for COVID-19. Tafenoquine is also being explored for its potential in treating fungal lung infections, tick-borne diseases, candidiasis, and other infectious as well as non-infectious conditions.
Another significant asset in the company's pipeline is Celgosivir, which is being developed as a therapeutic option for respiratory viruses and dengue fever. The development of Celgosivir highlights the company’s commitment to addressing a broad spectrum of infectious diseases with novel and effective treatments.
Founded in 2010 and headquartered in Washington, D.C., 60 Degrees Pharmaceuticals, Inc. combines innovative research with a focused approach to tackling some of the world’s most pressing health challenges. The company's strategic emphasis on advancing its drug candidates through clinical trials underscores its dedication to improving global health outcomes and combating infectious diseases.
|
